Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Russler-Germain

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Frontiers in Oncology|July 19, 2023
T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directionsDavid A Russler-Germain, Armin Ghobadi
Haematologica|March 12, 2026
To B or not to B, that is the question: the role of bleomycin in early stage Hodgkin lymphomaDavid A Russler-Germain, Nancy L Bartlett
Oncology (Williston Park, N.Y.)|January 4, 2021
Recent Advances in Antibody Drug Conjugates for LymphomaDavid A Russler-Germain, Brad S Kahl
Hematology. American Society of Hematology. Education Program|December 7, 2024
Sequencing bispecific antibodies and CAR T cells for FLDavid A Russler-Germain, Nancy L Bartlett
Leukemia & Lymphoma|October 8, 2020
A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphomaDavid A Russler-Germain, Marcus P Watkins, Nancy L Bartlett
Blood|October 5, 2023
Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysisDavid A Russler-Germain, Edward R Scheffer Cliff, Nancy L Bartlett
Elife|August 16, 2014
Microtubules provide directional information for core PCP functionMaja Matis, David A Russler-Germain, Qie Hu, et al.
Ejhaem|September 2, 2022
Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressionsAjay Major, Edward R Scheffer Cliff, Daniel A Ermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2024
US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell LymphomaEdward R Scheffer Cliff, David A Russler-Germain, C Joseph Ross Daval, et al.
Elife|March 15, 2016
Registered report: IDH mutation impairs histone demethylation and results in a block to cell differentiationAdam D Richarson, David A Scott, Olga Zagnitko, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|July 19, 2023
T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directionsDavid A Russler-Germain, Armin Ghobadi
Haematologica|March 12, 2026
To B or not to B, that is the question: the role of bleomycin in early stage Hodgkin lymphomaDavid A Russler-Germain, Nancy L Bartlett
Oncology (Williston Park, N.Y.)|January 4, 2021
Recent Advances in Antibody Drug Conjugates for LymphomaDavid A Russler-Germain, Brad S Kahl
Hematology. American Society of Hematology. Education Program|December 7, 2024
Sequencing bispecific antibodies and CAR T cells for FLDavid A Russler-Germain, Nancy L Bartlett
Leukemia & Lymphoma|October 8, 2020
A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphomaDavid A Russler-Germain, Marcus P Watkins, Nancy L Bartlett
Blood|October 5, 2023
Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysisDavid A Russler-Germain, Edward R Scheffer Cliff, Nancy L Bartlett
Elife|August 16, 2014
Microtubules provide directional information for core PCP functionMaja Matis, David A Russler-Germain, Qie Hu, et al.
Ejhaem|September 2, 2022
Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressionsAjay Major, Edward R Scheffer Cliff, Daniel A Ermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2024
US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell LymphomaEdward R Scheffer Cliff, David A Russler-Germain, C Joseph Ross Daval, et al.
Elife|March 15, 2016
Registered report: IDH mutation impairs histone demethylation and results in a block to cell differentiationAdam D Richarson, David A Scott, Olga Zagnitko, et al.
Pageof 4